Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034924.xml
Download PDF
Nuklearmedizin 2013; 52(04): 113-114
DOI: 10.1055/s-0037-1622117
DOI: 10.1055/s-0037-1622117
Editorial
131I sodium-iodide versus 56Fe surgical steel
Which is better for lateral lymph node metastases in differentiated thyroid cancer patients?Authors
Further Information
Publication History
received:
14 June 2013
accepted in revised form:
19 June 2013
Publication Date:
12 January 2018 (online)
-
References
- 1 Biermann M, Pixberg M, Riemann B. et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer. Nuklearmedizin 2009; 48: 89-98.
- 2 De Meer SG, Dauwan M, de Keizer B. et al. Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer. World J Surg 2012; 36: 1262-1267.
- 3 Handkiewicz-Junak D, Wloch J, Roskosz J. et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 2007; 48: 879-888.
- 4 Hay ID, Bergstralh EJ, Grant CS. et al. Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. Surgery 1999; 126: 1173-1181.
- 5 Haymart MR, Banerjee M, Yang D. et al. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer 2013; 119: 259-265.
- 6 Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
- 7 Randolph GW, Duh QY, Heller KS. et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22: 1144-1152.
- 8 Reiners C, Biko J, Haenscheid H. et al. Twenty-five years after. Chernobyl J Clin Endocrinol Metab. 2013
- 9 Reiners C, Hanscheid H, Luster M. et al. Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol 2011; 7: 589-595.
- 10 Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy. JAMA 1946; 132: 838-847.
- 11 Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours.. 7th ed. New-York: Wiley-Blackwell; 2009
- 12 Verburg FA, de Keizer B, Lam MG. et al. Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation. World J Surg 2007; 31: 2309-2314.
- 13 Verburg FA, Mader U, Tanase K. et al. Life expectancy is reduced in differentiated thyroid cancer patients <= 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 2013; 98: 172-180.
- 14 Verburg FA, Stokkel MP, Duren C. et al. No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 276-283.
- 15 Vrachimis A, Gerss J, Schober O, Riemann B. Peace of mind for patients with differentiated thyroid cancer?. Nuklearmedizin 2013; 52: 115-120.